CORE--CYTOGENETICS AND FISH

这一核心的功能与原来的补助金相比没有改变。 基本上，该核心旨在执行必要的实验室测试， 慢性粒细胞白血病患者造血细胞的常规表型 进入治疗的慢性期和急变期 实验方案和实验室分析见图1-2和表I。 包括光镜形态学、超微结构、bcr的Southern印迹 重排，免疫表型和细胞遗传学，以建立 CML的诊断 仅要求对细胞遗传学分析提供支持 费城染色体的百分比评估所需的 骨髓、外周血中的阳性（Ph+）细胞，或 治疗后患者的CD 34+选择细胞（项目1A-D）。 的 所用的细胞遗传学分析不仅包括经典的G显带， 方法，而且新开发的荧光原位杂交 （FISH）方法，通过使用 染色体特异性DNA探针。 我们的初步研究表明， FISH方法可有效检测9;22易位 在扩散不良的中期和间期核中， 常规细胞遗传学方法无法分析。 因此，包括 在核心中使用FISH应该大大提高我们的能力， 评估治疗的有效性和收集策略 正常二倍体祖细胞用于自体移植。 该核心还应 使我们能够比较FISH与细胞遗传学，以确定前者是否是 在检测CML微小残留病方面优于后者， 来预测复发 细胞遗传学和FISH分析的结果将 也可与项目II-VI中的其他检测结果相关联。

The function of this core is not changed from the original grant. Basically, this core is designed to perform necessary laboratory tests for the routine phenotyping of the hematopoietic cells from CML patients in chronic phase and blast crisis who are entered on the therapeutic protocols and laboratory analysis listed in Figures 1-2 and Table I. These include light morphology, ultrastructure, Southern blots for bcr rearrangement, immunophenotype, and cytogenetics to establish the diagnosis of CML. Support is requested only for cytogenetic analyses required for the evaluation of the percentage of Philadelphia-chromosome positive (Ph+) cells in the bone marrow, pheresed peripheral blood, or CD34+ selected cells of patients following therapy (Project 1A-D). The cytogenetic assays used will include not only the classical G-banding method but also the newly-developed fluorescent in situ hybridization (FISH) method that detects the 9;22 chromosomal translocation by using chromosome-specific DNA probes. Our preliminary studies demonstrated that the FISH method could be effectively used to detect the 9;22 translocation in poorly-spread metaphases and in interphase nuclei that were otherwise unanalyzable by the routine cytogenetic methods. Therefore, the inclusion of the use of FISH in the Core should significantly improve our ability to evaluate the effectiveness of therapy and the strategies for collecting normal diploid progenitor cells for autografts. This Core should also allow us to compare FISH with cytogenetics to determine if the former is better than the latter for detecting minimal residual disease in CML and for predicting relapse. The Results of cytogenetic and FISH analyses will also be correlated with results from other assays in Projects II-VI.